Giant Prolactinomas: Outcomes of Multimodal Treatments for 42 Cases with Long-Term Follow-Up

Abstract

Giant prolactinomas represent a rare entity of pituitary tumors so that the management of these patients is still a prevalent challenge at present. Paying special attention to the treatment strategy and outcomes, we presented a large series of 42 cases looking forward to share our understanding and experience in management of these patients. Male patients accounted for 71.4% of this series and were relatively younger (35.70±2.42 vs. 52.00±3.55 years, p=0.0011) and harbored bigger tumors (14.57 vs. 7.74 cm³, p=0.0179) compared to females. Almost all of these tumors showed suprasellar extension (97.6%) and cavernous sinus invasion (92.9%). Dopamine agonist represented an efficient method to control PRL concentrations (98.8%) and reduce tumor burdens (81.2 %). PRL normalization was detected in 13 out of the 27 patients initially treated with bromocriptine (BRC) whereas none of the 14 patients with first-line operation gained a normalization of PRL concentration after surgery. Although there was no reliable predictor of tumor response, First PRL reduction was a predictive criterion for the nadir PRL level during the long-time period of follow-up for first-line bromocriptine treatment. In conclusion, patients with giant prolactinomas did not gain more benefits from initial surgery. Dopamine agonist (BRC) should be first-line treatment for giant prolactinomas whereas operation merely served as a remedy for acute compression symptoms and dopamine agonist resistance. Consecutive monitoring of serum PRL levels in the early stage of initial BRC treatment is useful for evaluation of therapeutic effect and further therapeutic decision.

Key words

giant prolactinoma - prolactin - dopamine agonist - bromocriptine

• References

• 1 Daly AF, Rixhon M, Adam C. et al. High prevalence of pituitary adenomas: A cross-sectional study in the province of Liege, Belgium. The Journal of Clinical Endocrinology and Metabolism 2006; 91: 4769
• 2 Raappana A, Koivukangas J, Ebeling T. et al. Incidence of pituitary adenomas in Northern Finland in 1992-2007. The Journal of Clinical Endocrinology and Metabolism 2010; 95: 4268-4275
• 3 Colao A, Savastano S. Medical treatment of prolactinomas. Nature Reviews Endocrinology 2011; 7: 267-278 10.1038/nrendo.2011.37
• 4 Maiter D, Delgrange E. Therapy of endocrine disease: The challenges in managing giant prolactinomas. European journal of endocrinology / European Federation of Endocrine Societies 2014; 170: R213-R227 10.1530/EJE-14-0013
• 5 Espinosa E, Sosa E, Mendoza V. et al. Giant prolactinomas: Are they really different from ordinary macroprolactinomas?. Endocrine 2016; 52: 652-659 10.1007/s12020-015-0791-7
• 6 Corsello SM, Ubertini G, Altomare M. et al. Giant prolactinomas in men: Efficacy of cabergoline treatment. Clinical Endocrinology 2003; 58: 662-670
• 7 Shrivastava RK, Arginteanu MS, King WA. et al. Giant prolactinomas: Clinical management and long-term follow up. Journal of Neurosurgery 2002; 97: 299
• 8 Cho EH, Lee SA, Chung JY. et al. Efficacy and safety of cabergoline as first line treatment for invasive giant prolactinoma. Journal of Korean Medical Science 2009; 24: 874-878 10.3346/jkms.2009.24.5.874
• 9 Gillam MP, Molitch ME, Lombardi G. et al. Advances in the treatment of prolactinomas. Endocrine Reviews 2006; 27: 485-534 10.1210/er.2005-9998
• 10 Dash S, Annamalai AK, Simpson HL. et al. Acute shrinkage of a giant prolactinoma, masquerading as an erosive skull base tumour, with cabergoline. QJM 2013; 106: 85
• 11 Besser M. Criteria for medical as opposed to surgical treatment of prolactinomas. Acta Endocrinologica 1993; 129 (Suppl. 01) 27
• 12 Moraes AB, Silva CM, Vieira Neto L. et al. Giant prolactinomas: The therapeutic approach. Clin Endocrinol (Oxf) 2013; 79: 447-456 10.1111/cen.12242
• 13 Shrivastava RK, Arginteanu MS, King WA. et al. Giant prolactinomas: Clinical management and long-term follow up. Journal of Neurosurgery 2002; 97: 299-306
• 14 Corsello SM, Ubertini G, Altomare M. et al. Giant prolactinomas in men: Efficacy of cabergoline treatment. Clinical Endocrinology 2003; 58: 662-670
• 15 Shimon I, Sosa E, Mendoza V. et al. Giant prolactinomas larger than 60 mm in size: A cohort of massive and aggressive prolactin-secreting pituitary adenomas. Pituitary 2016; 19: 429-436 10.1007/s11102-016-0723-4
• 16 Andujar-Plata P, Villar-Taibo R, Ballesteros-Pomar MD. et al. Long-term outcome of multimodal therapy for giant prolactinomas. Endocrine 2017; 55: 231-238 10.1007/s12020-016-1129-9
• 17 Delgrange E, Daems T, Verhelst J. et al. Characterization of resistance to the prolactin-lowering effects of cabergoline in macroprolactinomas: A study in 122 patients. European Journal of Endocrinology 2009; 160: 747-752
• 18 Yarman S, Kurtulmus N, Bilge A. Optimal effective doses of cabergoline and bromocriptine and valvular leasions in men with prolactinomas. Neuro Endocrinology Letters 2012; 33: 340
• 19 Bevan JS, Webster J, Burke CW. et al. Dopamine agonists and pituitary tumor shrinkage. Endocrine reviews 1992; 13: 220-240
• 20 Hsu CY, Guo WY, Chien CP. et al. MIB-1 labeling index correlated with magnetic resonance imaging detected tumor volume doubling time in pituitary adenoma. European journal of endocrinology / European Federation of Endocrine Societies 2010; 162: 1027-1033 10.1530/EJE-09-1100
• 21 Comtois R, Robert F, Hardy J. Immunoradiometric assays may miss high prolactin levels. Annals of Internal Medicine 1993; 119: 173
• 22 Ciccarelli A, Daly AF, Beckers A. The epidemiology of prolactinomas. Pituitary 2005; 8: 3
• 23 Leonard MP, Nickel CJ, Morales A. Hyperprolactinemia and impotence: Why, when and how to investigate. Journal of Urology 1989; 142: 992-994
• 24 Guay AT, Sabharwal P, Varma S. et al. Delayed diagnosis of psychological erectile dysfunction because of the presence of macroprolactinemia. The Journal of Clinical Endocrinology and Metabolism 1996; 81: 2512
• 25 Delgrange E, Trouillas J, Maiter D. et al. Sex-related difference in the growth of prolactinomas: A clinical and proliferation marker study. The Journal of clinical endocrinology and metabolism 1997; 82: 2102-2107
• 26 Chattopadhyay A, Bhansali A, Masoodi SR. Long-term efficacy of bromocriptine in macroprolactinomas and giant prolactinomas in men. Pituitary 2005; 8: 147-154 10.1007/s11102-005-5111-4
• 27 Gillam MP, Molitch ME, Lombardi G. et al. Advances in the treatment of prolactinomas. Endocrine reviews 2006; 27: 485
• 28 Shimon I, Benbassat C, Hadani M. Effectiveness of long-term cabergoline treatment for giant prolactinoma: Study of 12 men. European journal of endocrinology / European Federation of Endocrine Societies 2007; 156: 225-231 10.1530/EJE-06-0646
• 29 Yang MS, Hong JW, Lee SK. et al. Clinical management and outcome of 36 invasive prolactinomas treated with dopamine agonist. Journal of neuro-oncology 2011; 104: 195-204
• 30 Iglesias P, Macho LP, Díez JJ. Resolution of macroprolactinoma-induced symptomatic hydrocephalus following cabergoline therapy. Age Ageing 2004; 33: 410-412
• 31 Cackett P, Eunson G, Bath L. et al. Proptosis as the presenting sign of giant prolactinoma in a prepubertal boy: Successful resolution of hydrocephalus by use of medical therapy. Future Oncology 2012; 8: 1621-1626
• 32 Perani D, Colombo N, Scotti G. et al. Rapid size reduction of giant prolactinoma following medical treatment. Journal of Computer Assisted Tomography 1984; 8: 131
• 33 Arafah BM. Reversible hypopituitarism in patients with large nonfunctioning pituitary adenomas. The Journal of Clinical Endocrinology and Metabolism 1986; 62: 1173
• 34 Gillam MP, Middler S, Freed DJ. et al. The novel use of very high doses of cabergoline and a combination of testosterone and an aromatase inhibitor in the treatment of a giant prolactinoma. The Journal of clinical endocrinology and metabolism 2002; 87: 4447-4451 10.1210/jc.2002-020426
• 35 Molitch ME. Medical treatment of prolactinomas. Endocrinology and Metabolism Clinics of North America 1999; 28: 143-169